New use for foralumab in CAR T-cell therapy
Tiziana has a fully human therapeutic monoclonal antibody, foralumab, currently being developed for nasal, inhaled and oral delivery to treat autoimmune disease and COVID-19; it is the only fully human anti-CD3 monoclonal. Precision Biosciences, Tiziana’s new US partner, is developing “off-the-shelf” (allogeneic) CAR T-cell therapies. CAR T-cell therapy is a powerful new therapy type used for some blood cancers. To make it work, existing T-cells in patients need to be depleted first. This is done using highly toxic chemotherapy agents. The hypothesis being explored is to use foralumab to reduce or replace this chemotherapy in order to achieve a safer treatment regimen and enable more patients to access effective allogeneic CAR T-cell therapy.
Quick facts: Tiziana Life Sciences PLC
Price: 1.59 USD
Market Cap: $154.72 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE